Objective To study the relationship between metalloproteinases (MMPs) and breast cancer. Methods The literature in recent years on the relationship between the expression of MMPs and breast cancer was reviewed. Results The balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs) is keeping normally kept in human body. Many of the studies showed that the expression of MMPs is increased in breast cancer. Conclusion The growth, invasion and metastasis of breast cancer is closely related with the increased expression of MMPs. This suggests that MMPs is a valuable prognostic marker and TIMPs would be a novel drug against cancer.
【摘要】目的探討乳腺癌仿根治術中保留肋間臂神經（ICBN）的臨床意義。方法將184例Ⅰ～Ⅲ期乳腺癌患者隨機均分為兩組，實驗組術中保留ICBN； 對照組術中均切除ICBN。并對兩組患者術后進行隨訪觀察。結果兩組乳腺癌切除均行常規仿根治術，手術過程順利，平均手術時間實驗組為（140±10） min，對照組為（130±10） min，實驗組92例術中有80例成功保留ICBN，且患側上肢感覺障礙發生率為6.25%（5/80），對照組發生率為54.3%（50/92），兩組比較差異有顯著性意義（χ2=45.51，P＜0.01），經術后3個月～3年隨訪，上肢感覺障礙實驗組5例中有2例1年后好轉； 對照組50例中1年后好轉6例，兩組腫瘤均無局部復發。結論在乳腺癌仿根治術中保留ICBN可有效地防止患側上肢感覺障礙的發生。
【摘要】 目的 比較酸性成纖維細胞生長因子(acid fibroblast growth factor,aFGF或FGF1)在正常乳腺組織、乳腺良性腫瘤及乳腺癌中的表達差異,探討FGF1與乳腺癌血管生成的關系。方法 應用免疫組織化學(immunohistochemistry,IHC)SP法檢測FGF1在40例乳腺癌組織、12例良性乳腺腫瘤組織及12例正常乳腺組織中的表達情況；以CD34抗體標記血管內皮細胞CD34抗原行乳腺癌組織微血管密度(micro vessel density,MVD)計數。〖HTH〗結果〖HTSS〗 FGF1在40例乳腺癌中的陽性表達率（57.5%，23/40)顯著高于12例乳腺良性腫瘤組織中陽性表達率(16.7%,2/12)以及正常乳腺組織陽性表達率(0,0/12),差異有統計學意義(Plt;0.05)；良性腫瘤組FGF1表達率和正常乳腺組織比較無統計學意義(Pgt;0.05)。40例乳腺癌組織MVD計數為(70.17±29.33)個/HP,在23例FGF1陽性組中MVD計數為(89.48±23.23)個/HP,顯著高于17例陰性組(44.06±12.53)個/HP,差異有統計學意義(Plt;0.05)。〖HTH〗結論 〖HTSS〗FGF1可能參與乳腺癌微血管生成。
Objective To investigate the impacts of neoadjuvant chemotherapy on the expression of insulin-like growth factor-1 receptor (IGF-1R) and on operation procedure and the significance of prognosis. Methods The expression of IGF-1R in 40 patients with breast cancer before and after neoadjuvant chemotherapy was measured by immunohistochemistry. The diagnosis was proved by core biopsy. All the patients took the TAC chemotherapy regimen. Modified radical operation was performed after two chemotherapy cycles and the IGF-1R expression was measured again. The clinical effect of neoadjuvant chemotherapy was assessed according to WHO criterion by measuring the size of tumor by physical examination and B type ultrasound. Results After neoadjuvant chemotherapy the tumor size shrank in 29 patients, there was no CR (complete response) or PD (progressed disease) to be documented. IGF-1R expression could be downregulated in 25 patients. Conclusion Neoadjuvant chemotherapy can inhibit the tumor growth by downregulation of the expression of IGF-1R.
ObjectiveTo explore the influence of sentinel lymph node (SLN) status on the prognosis of elderly breast cancer patients ≥70 years old, and to screen patients who may be exempted from sentinel lymph node biopsy (SLNB), so as to guide clinical individualized treatment for such patients. MethodsA retrospective analysis was made on 270 breast cancer patients aged ≥70 years old who underwent SLNB in the Affiliated Hospital of Southwest Medical University from 2012 to 2021. The clinicopathological characteristics of the total cases were compared according to the status of SLN. Kaplan-Meier method was used to draw the survival curve, and the influence of SLN status on the overall survival (OS) time, local recurrence (LR) and distant metastasis (DM) of patients were analyzed, and used log-rank to compare between groups. At the same time, the patients with hormone receptor (HR) positive were analyzed by subgroup. The differences between groups were compared by single factor χ2 test, and multivariate Cox regression model was used to analyze and determine the factors affecting OS, LR and DM of patients. ResultsThe age of 270 patients ranged from 70 to 95 years, with a median age of 74 years. One hundred and sixty-nine (62.6%) patients’ tumor were T2 stage. Invasive ductal carcinoma accounted for 83.0%, histological gradeⅡ accounted for 74.4%, estrogen receptor positive accounted for 78.1%, progesterone receptor positive accounted for 71.9%, and human epidermal growth factor receptor 2 negative accounted for 83.3%. The number of SLNs obtained by SLNB were 1-9, and the median was 3. SLN was negative in 202 cases (74.8%) and positive in 68 cases (25.2%). Thirty-five patients (13.0%) received axillary lymph node dissection. There was no significant difference in LR between the SLN positive group and the SLN negative group (P>0.05), but the SLN negative group had fewer occurrences of DM (P=0.001) and longer OS time (P=0.009) compared to the SLN positive group. The results of univariate and multivariate analysis suggest that the older the patient, the shorter the OS time and the greater the risk of DM. Analysis of HR positive subgroups showed that SLN status did not affect patient survival and prognosis, but age was still associated with poor OS time and DM. ConclusionsFor patients with invasive ductal carcinoma of breast in T1-T2 stage, HR positive, clinical axillary lymph nodes negative, and age ≥70 years old, SLNB may be exempted. According to the patient’s performance or tumor biological characteristics, patients who need systemic adjuvant chemotherapy may still consider SLNB.